Loan Agreement with BioFund Capital Management LLC_#160;

Current Report No: 24/2024_#160;

Date: November 29, 2024_#160;

Legal Basis: Article 17(1) of the MAR Regulation -inside information._#160;

The Management Board of Medicalgorithmics S.A.,headquartered in Warsaw (the "Company"), announces that on November 29,2024, it entered into a loan agreement (the "Agreement") with theCompany's shareholder, BioFund Capital Management LLC ("BioFund"), foran amount up to USD 3,000,000, payable in four tranches._#160;

The first two tranches will be disbursed by December31, 2024, while the third and fourth tranches, amounting to USD1,000,000 each, will be paid on March 20, 2025, and May 20, 2025,respectively. According to the Agreement, the disbursement of the thirdand fourth tranches is contingent upon achieving specified cash balancethresholds on all bank accounts of the Company's capital group byFebruary 28, 2025, and April 30, 2025, respectively._#160;

The loan will bear a fixed interest rate of 18.5%. Itwill be repaid in 24 equal principal and interest installments startingOctober 31, 2025, with the final installment due by September 30, 2027.Repayment will be made in USD._#160;

As collateral for obligations under the Agreement,the Company has issued a statement of voluntary submission toenforcement under Article 777 § 1(5) of the Polish Civil Procedure Code,covering its entire assets, up to an amount of USD 8,500,000._#160;

The Company will pay BioFund a commission of 3% ofthe revenues generated by the Company from new clients, defined as thosewho enter into agreements with the Company from the date of the firsttranche disbursement until the full repayment (or early repayment) ofthe loan, for services related to software-based ECG or VCAST dataanalysis during this period. Revenues from equipment sales, repairs, orother services outside the scope of software-based data analysis areexcluded._#160;

If the Company makes an early repayment of any loaninstallment, in whole or in part, before the scheduled due date, BioFundwill receive a fee of 15% (annualized) of the product of the earlyrepayment amount and the number of days remaining until the scheduledrepayment date._#160;

If the Company does not request the disbursement ofthe third or fourth tranche, and BioFund does not disburse them, theCompany will pay BioFund a fee of 15% of the undisbursed tranche amountunless the Company secures a loan or other financing from a differententity to which it submitted a financing request. The alternativefinancing must not be less than the undisbursed tranches and must havecosts no higher than those agreed with BioFund under the Agreement._#160;

In the event of a breach, BioFund may demand earlyrepayment of the entire loan amount, including interest, within 30business days of receiving such a demand. It may also cease futuredisbursements. Breaches include:_#160;

(i) failure to meet the cash balance thresholdsspecified in the Agreement,_#160;

(ii) entering into a financing agreement withoutBioFund's consent unless it is on more favorable terms,_#160;

(iii) failure to execute the financial plan,_#160;

(iv) failure to establish collateral, and_#160;

(v) asset disposal without BioFund's consent._#160;

Additionally, if the first tranche is not disbursedwithin three business days, the Agreement will automatically terminate._#160;

The Management Board also informs that BioFund hasterminated the loan facility agreement previously disclosed in CurrentReport No. 16/2024._#160;